FDA Grants Priority Review to BridgeBio's Dwarfism Drug Filing
BBIO wins FDA priority review for infigratinib, potentially making it the first approved oral therapy for achondroplasia.
Stock Taper 
BMRN
$54.80
▼ DOWN 0.17% (-0.10)
KEY STATISTICS
Market Cap$10.61 B
52w High$70.98
52w Low$49.26
Dividend Yield—
Frequency—
P/E26.34
Volume2.15M
Shares Out.193.28M
COMPANY
LEADERSHIP
CHIEF EXECUTIVE
Alexander Hardy
COMPENSATION 2026
Salary$1,130,769
Stock Awards$16,833,629
Incentive Plan Pay$1,644,500
All Other Comp.$409,355
Total$21,927,563
ABOUT
SECTOR
Healthcare
WENT PUBLIC
July 26, 1999
METHOD OF GOING PUBLIC
IPO
FULL TIME EMPLOYEES
3,221
PRICE TARGET
Target High$124.00
Target Low$59.00
Target Median$90.00
Target Consensus$90.88
UPCOMING EARNINGS
DateOct 26, 2026
DayMonday
Rev. Est.$1.02B
OCT
26
MON
ETFS HOLDING THIS STOCK
ETFS HOLDING
343
LISTED HERE
10
RANKED BY POSITION SIZE
INSTITUTIONAL OWNERSHIP
SHARES OWNED
61.43%
HOLDERS
980
TOP 8 OF 980 · RANKED BY POSITION SIZE
PRICE
$54.80 ▼ DOWN 0.17% (−$0.10)About BioMarin Pharmaceutical Inc.
https://www.biomarin.com ↗BioMarin develops and commercializes therapies for rare diseases, including enzyme replacements, gene therapies, and treatments for conditions like MPS, PKU, and hemophilia, serving global markets through collaborations and specialty distribution.
INDUSTRY
Biotechnology
A PRODUCT BIOMARIN PHARMACEUTICAL INC. IS KNOWN FOR
Voxzogo (vosoritide)
Voxzogo is a daily injection approved for increasing growth in children with achondroplasia, driving BioMarin's revenue growth through strong market adoption and strategic commercial focus.
BioMarin Pharmaceutical in 2025
SENTIMENT: + POSITIVE
ACQUISITION · DECEMBER 2025
BioMarin Announces Its Largest-Ever Acquisition, Buying Amicus Therapeutics for $4.8 Billion
In its most significant M&A activity to date, BioMarin Pharmaceutical Inc. entered into a definitive agreement to acquire fellow rare disease drugmaker Amicus Therapeutics for approximately $4.8 billion in an all-cash transaction. This strategic move is intended to accelerate BioMarin's revenue growth and strengthen its portfolio with the addition of two growing products, Galafold for Fabry disease and Pombiliti-Opfolda for Pompe disease.
ACQUISITION · DECEMBER 2025 · ANNOUNCED
BioMarin to Acquire Amicus Therapeutics for $4.8 Billion, Cementing Leadership in Rare Diseases
In a major strategic move to accelerate growth and diversify its revenue, BioMarin announced its agreement to acquire Amicus Therapeutics. The deal significantly expands BioMarin's portfolio with two marketed therapies for Fabry and Pompe diseases, strengthening its position as a global leader in treatments for rare genetic conditions.
Latest News
EARLIER COVERAGE
BioMarin Appoints Cara Bauer as Chief People Officer
Ms. Bauer Brings More Than 25 Years of Experience in Human Resources, Across Biotechnology and Technology Industries Appointment Effective Oct. 5, 2026 SAN RAFAEL, Calif., Oct. 5, 2026 /PRNewswire/ -- BioMarin Pharmaceutical Inc. (Nasdaq: BMRN) announced today that Cara Bauer, Ph.D.
BioMarin reports five-year Pompe disease data showing durable motor function
A BioMarin combination therapy helped adults with late-onset Pompe disease maintain walking distance over five years of continuous therapy. Respiratory function remained relatively stable, with no new safety signals identified.
BioMarin Announces Five-Year Phase 3 Data for POMBILITI® (cipaglucosidase alfa-atga) + OPFOLDA® (miglustat) at World Muscle Society Annual Congress
Long-term data reinforce durable efficacy and safety of POMBILITI + OPFOLDA in late-onset Pompe disease SAN RAFAEL, Calif., Oct. 2, 2026 /PRNewswire/ -- BioMarin Pharmaceutical Inc. (Nasdaq: BMRN) today announced new data evaluating the efficacy and safety of POMBILITI® (cipaglucosidase alfa-atga) + OPFOLDA® (miglustat) in late-onset Pompe disease (LOPD) were presented at the 31st Annual Congress of the World Muscle Society (WMS), in Hiroshima, Japan.
RATINGS SNAPSHOT
Overall rating: B
Discounted Cash Flow5
Return On Equity2
Return On Assets4
Debt To Equity1
Price To Earnings1
Price To Book3
Overall Score3
MOST RECENT ANALYST GRADES
GRADE SUMMARY
BUY 7
OVERWEIGHT 4
OUTPERFORM 4
NEUTRAL 1
SECTOR PERFORM 1
MARKET PERFORM 1
HOLD 1
19 GRADES IN THE LAST 12 MONTHS
SECTORS PEERS
| PEER | PRICE | |
|---|---|---|
 VRTX | $504.43 | COMPARE |
 MRNA | $189.85 | COMPARE |
 RVMD | $198.93 | COMPARE |
 ALNY | $222.39 | COMPARE |
 INSM | $99.22 | COMPARE |
 EXEL | $57.94 | COMPARE |
 ASND | $224.44 | COMPARE |
 HALO | $110.28 | COMPARE |
TRADES BY CONGRESS
HOUSE TRADES
Ro Khanna
Sale
2023-03-14
Daniel Goldman
Sale (Full)
2023-03-06
Josh Gottheimer
Sale (Full)
2021-10-18
Josh S. Gottheimer
Sale (Full)
2021-10-18
INSIDER TRADES
★
OFFICER: EVP, CHIEF R&D OFFICER
Friberg Gregory R
Sale · 4.1K shares
2026-09-30
★
DIRECTOR:
Plenge Robert M
— · —
2026-09-10
★
DIRECTOR
Plenge Robert M
Purchase · 6.1K shares
2026-09-10
★
OFFICER: EVP, CHIEF LEGAL OFFICER
Davis George Eric
Sale · 17.6K shares
2026-09-02